Supernus Pharmaceuticals (SUPN) to Post Quarterly Earnings on Tuesday

Supernus Pharmaceuticals (NASDAQ:SUPN) is projected to issue its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.4225 per share and revenue of $205.3120 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $44.63 on Friday. The company’s 50-day moving average price is $46.27 and its two-hundred day moving average price is $49.10. Supernus Pharmaceuticals has a one year low of $32.83 and a one year high of $59.68. The stock has a market capitalization of $2.59 billion, a PE ratio of -87.51, a price-to-earnings-growth ratio of 0.95 and a beta of 0.54.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $62.83.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of SUPN. Vestcor Inc acquired a new stake in Supernus Pharmaceuticals in the 3rd quarter valued at about $67,000. EverSource Wealth Advisors LLC bought a new stake in Supernus Pharmaceuticals in the second quarter valued at approximately $51,000. Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $55,000. Osaic Holdings Inc. lifted its position in shares of Supernus Pharmaceuticals by 211.5% in the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock valued at $63,000 after buying an additional 1,328 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Supernus Pharmaceuticals in the third quarter valued at approximately $128,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.